MicroRNAs Modulation and Clinical Outcomes at 1 Year of Follow-Up After Excision of Subcutaneous Abdominal Fat in Overweight Patients with Pre-Diabetes Treated with Metformin vs. Placebo

Background: obese pre-diabetics have altered expression of cytokines, and sirtuin-1, that might influence myocardial function via microRNAs (miRs) expression. Objectives: to evaluate inflammatory/oxidative stress, miRs’ expression and cardiovascular function in obese pre-diabetics randomly assigned to metformin therapy vs. placebo vs. normo-glycemics at 12 months of follow-up. Materials and methods: eighty-three obese patients enrolled for abdominoplastic surgery, were divided in pre-diabetics (n 55), normo-glycemics (n 28), and assigned to hypocaloric diet. Pre-diabetics were randomly assigned to metformin (n 23) or to placebo (n 22) plus hypocaloric diet. Results: at enrollment, pre-diabetics obese vs. normo-glycemic presented higher values of glucose, insulin resistance (HOMA-IR), inflammatory/oxidative stress markers, miR-195 and miR-27, and lower values of sirtuin-1 (p<0.05). At 12 months of follow up, obese pre-diabetics with metformin vs. placebo experienced significant reduction of glucose values, HOMA-IR, and inflammatory/oxidative stress markers, with significant reduction of intima-media thickness (IMT), septum and posterior wall thickness, and left ventricle mass (LVM), (p <0.05). At 12 months of follow-up, obese pre-diabetics with placebo vs. normo-glycemics had higher values of inflammatory/oxidative stress markers, higher values of IMT, septum and posterior wall thickness, LVM, and myocardial performance index (MPI), (p<0.05). Obese pre-diabetics in metformin vs. placebo, and obese pre-diabetics with placebo vs. normoglycemics, had significant differences about IMT, MPI, and LVM (p<0.05). Obese pre-diabetics in metformin vs. placebo showed significant reduction of serum miR-195 and miR-27 (p<0.05). Obese pre-diabetics in metformin vs. normoglycemics showed higher expression of serum miR-195 and miR-27 ( p<0.05). Finally, we found inverse relation between IMT and insulin (R -0.351), HOMA-IR (R -0.340), miR-195 (R -0.355), miR-27 (R -0.181); between LVEF and Insulin (R -0.332), HOMA-IR (R -0.142), miR-195 (R -0.297) and miR-27 (R -0.163). We found inverse correlation between LVM and sirtuin-1 (R -0.272), Insulin (R -0.810), HOMA-IR (R-0.183), miR-195 (R -0.446) and miR-27 (R-0.433), and direct correlation with interleukin-6 (R 0.195). MPI inversely linked to miR-195 (R -0.260) and miR-27 (R -0.591). Conclusion: in obese pre-diabetics metformin therapy significantly reduces inflammation/oxidative stress, circulating miR-195 and miR-27, causing reduction of LVM, IMT and amelioration of cardiac performance.

[1]  S. Fallah,et al.  The expression levels of miRNAs- 27a and 23a in the peripheral blood mononuclear cells (PBMCs) and their correlation with FOXO1 and some inflammatory and anti-inflammatory cytokines in the patients with coronary artery disease (CAD). , 2020, Life sciences.

[2]  C. Lang,et al.  A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial , 2019, European heart journal.

[3]  F. Milagro,et al.  MicroRNAs and other non-coding RNAs in adipose tissue and obesity: emerging roles as biomarkers and therapeutic targets. , 2019, Clinical science.

[4]  Lei Wang,et al.  MiR-1955 p Promotes Cardiomyocyte Hypertrophy by Targeting MFN 2 and FBXW 7 , 2019 .

[5]  S. Balci,et al.  Profiles of Circulating MiRNAs Following Metformin Treatment in Patients with Type 2 Diabetes , 2018, Journal of medical biochemistry.

[6]  J. Weaver,et al.  Anti-Angiogenic miR-222, miR-195, and miR-21a Plasma Levels in T1DM Are Improved by Metformin Therapy, Thus Elucidating Its Cardioprotective Effect: The MERIT Study , 2018, International journal of molecular sciences.

[7]  M. Barbieri,et al.  Inflammatory Cytokines and SIRT1 Levels in Subcutaneous Abdominal Fat: Relationship With Cardiac Performance in Overweight Pre-diabetics Patients , 2018, Front. Physiol..

[8]  M. Puzianowska-Kuźnicka,et al.  NGS Reveals Molecular Pathways Affected by Obesity and Weight Loss-Related Changes in miRNA Levels in Adipose Tissue , 2017, International journal of molecular sciences.

[9]  Xinghui Sun,et al.  Emerging Roles for MicroRNAs in Diabetic Microvascular Disease: Novel Targets for Therapy. , 2017, Endocrine reviews.

[10]  N. Lundbom,et al.  Weight Loss Is Associated With Increased NAD(+)/SIRT1 Expression But Reduced PARP Activity in White Adipose Tissue. , 2016, The Journal of clinical endocrinology and metabolism.

[11]  Yong Yu,et al.  Silencing of miR-195 reduces diabetic cardiomyopathy in C57BL/6 mice , 2015, Diabetologia.

[12]  Peter Arner,et al.  MicroRNA regulatory networks in human adipose tissue and obesity , 2015, Nature Reviews Endocrinology.

[13]  Victor Mor-Avi,et al.  Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, European heart journal cardiovascular Imaging.

[14]  S. Chakrabarti,et al.  miR-195 regulates SIRT1-mediated changes in diabetic retinopathy , 2014, Diabetologia.

[15]  G. Paolisso,et al.  Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non‐responders , 2013, European journal of heart failure.

[16]  D. Karolina,et al.  Circulating miRNA profiles in patients with metabolic syndrome. , 2012, The Journal of clinical endocrinology and metabolism.

[17]  Johan Auwerx,et al.  Sirtuins as regulators of metabolism and healthspan , 2012, Nature Reviews Molecular Cell Biology.

[18]  V. Basevi,et al.  Standards of Medical Care in Diabetes—2012 , 2011, Diabetes Care.

[19]  Jianping Ye,et al.  A role of miR‐27 in the regulation of adipogenesis , 2009, The FEBS journal.

[20]  Christopher B. Kendall,et al.  Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. , 2008, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[21]  S. Daniels,et al.  Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. , 1992, Journal of the American College of Cardiology.